Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Plaques

- PMLiVE

Roche launches two antibodies to identify mutation status in brain cancer patients

Knowing a patient’s key mutations can help clinicians provide personalised care

- PMLiVE

Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine

It was questioned whether the companies had used their market power to boost sales of their eye disease drug

Biogen Idec building

Safety-related change to label for Biogen’s Alzheimer’s drug Aduhelm approved by FDA

Larger areas of bleeding on the brain have been reported in some patients taking the drug

- PMLiVE

Roche reports positive results for crovalimab as rare blood disease treatment

The drug was shown to be as effective as current treatment, with less frequent dosing

- PMLiVE

Roche’s Polivy recommended by NICE for lymphoma therapy

Around 5,500 people in England are diagnosed with the aggressive blood cancer each year

- PMLiVE

Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer

Tecentriq in combination with Avastin significantly improved recurrence-free survival

- PMLiVE

Roche’s influenza medicine approved by EC for children

Xofluza is now the first single-dose, oral influenza medicine approved in Europe for children

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

Biogen Idec building

Biogen and Alcyone Therapeutics partner in deal worth over $50m

The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis

Biogen Idec building

Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab

Genentech will have sole decision-making rights on glofitamab's commercialisation in the US

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links